Overexpression of the hif hydroxylases phd1, phd2, phd3 and fih are individually and collectively unfavorable prognosticators for nsclc survival

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Andersen, Sigve ^a,b   Donnem, Tom ^a,b   Stenvold, Helge ^a,b   Al Saad, Samer ^a,b   Al Shibli, Khalid ^a,c   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR INHIBITING HIF; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE 1; PROLYL HYDROXYLASE 2; PROLYL HYDROXYLASE 3; UNCLASSIFIED DRUG; DIOXYGENASE; EGLN1 PROTEIN, HUMAN; EGLN3 PROTEIN, HUMAN; HIF1AN PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; REPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; SENSOR; STROMA; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR CELL; UNIVARIATE ANALYSIS; BIOSYNTHESIS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DIOXYGENASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN-PROLINE DIOXYGENASE; PROGNOSIS; REPRESSOR PROTEINS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 80051934217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023847     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Sangha R, Price J, Butts CA, (2010) Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist 15: 862-872 theoncologist.2009-0186 [pii];10.1634/theoncologist.2009-0186 [doi].
3. Le QT, Chen E, Salim A, Cao H, Kong CS, et al. (2006) An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers. Clin Cancer Res 12: 1507-1514.
4. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186 10.1056/NEJM197111182852108 [doi].
5. Semenza GL, (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634 onc2009441 [pii];10.1038/onc.2009.441 [doi].
6. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54 S0092-8674(01)00507-4 [pii].
7. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472 10.1126/science.1059796 [doi];1059796 [pii].
8. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, et al. (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465 doi:10.1074/jbc.M406026200 [doi];M406026200 [pii].
9. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, et al. (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090 10.1093/emboj/cdg392 [doi].
10. Stolze IP, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, et al. (2004) Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. J Biol Chem 279: 42719-42725 10.1074/jbc.M406713200 [doi];M406713200 [pii].
11. Chan DA, Giaccia AJ, (2010) PHD2 in tumour angiogenesis. Br J Cancer 103: 1-5 6605682 [pii];10.1038/sj.bjc.6605682 [doi].
12. Jokilehto T, Jaakkola PM, (2010) The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 14: 758-770 JCMM1030 [pii];10.1111/j.1582-4934.2010.01030.x [doi].
13. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, et al. (2005) Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 47: 602-610 HIS2280 [pii];10.1111/j.1365-2559.2005.02280.x [doi].
14. Giatromanolaki A, Koukourakis MI, Pezzella F, Turley H, Sivridis E, et al. (2008) Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Lett S0304-3835(07)00588-5 [pii];10.1016/j.canlet.2007.11.041 [doi].
15. Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, et al. (2010) Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer S0169-5002(10)00483-6 [pii];10.1016/j.lungcan.2010.10.006 [doi].
16. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20: 2417-2428.
17. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, et al. (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13: 6649-6657.
18. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, et al. (2008) Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 3: 963-970.
19. Donnem T, Andersen S, Al Shibli K, Al Saad S, Busund LT, et al. (2010) Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer.
20. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, et al. (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64: 844-856.
21. Boddy JL, Fox SB, Han C, Campo L, Turley H, et al. (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11: 7658-7663 11/21/7658 [pii];10.1158/1078-0432.CCR-05-0460 [doi].
22. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, et al. (2008) Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res 14: 6634-6639 14/20/6634 [pii];10.1158/1078-0432.CCR-07-5258 [doi].
23. Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, et al. (2010) Expression of key hypoxia sensing prolyl-hydroxylases PHD1,-2 and-3 in pancreaticobiliary cancer. Histopathology 56: 908-920 HIS3566 [pii];10.1111/j.1365-2559.2010.03566.x [doi].
24. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, et al. (2010) Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 70: 357-366 0008-5472.CAN-09-1876 [pii];10.1158/0008-5472.CAN-09-1876 [doi].
25. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, et al. (2006) Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 12: 1080-1087 12/4/1080 [pii];10.1158/1078-0432.CCR-05-2022 [doi].
26. Su Y, Loos M, Giese N, Hines OJ, Diebold I, et al. (2010) PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer 103: 1571-1579 6605936[pii];10.1038/sj.bjc.6605936 [doi].
27. Tan EY, Yan M, Campo L, Han C, Takano E, et al. (2009) The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100: 405-411 6604844 [pii];10.1038/sj.bjc.6604844 [doi].
28. Mazzone M, Dettori D, Leite de OR, Loges S, Schmidt T, et al. (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851 S0092-8674(09)00068-3 [pii];10.1016/j.cell.2009.01.020 [doi].
29. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E, (2008) PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci U S A 105: 4745-4750 0705680105 [pii];10.1073/pnas.0705680105 [doi].
30. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, et al. (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538 S1535-6108(09)00144-5 [pii];10.1016/j.ccr.2009.04.010 [doi].
31. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, et al. (2003) Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res 63: 8777-8783.
32. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, et al. (2010) Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481-501 10.1089/ars.2009.2711 [doi].
33. Rami-Porta R, Crowley JJ, Goldstraw P, (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15: 4-9 atcs/2009_15_1/10 [pii].
34. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, et al. (2008) The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 99: 1476-1483.
35. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, et al. (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14: 5220-5227.
36. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, et al. (2008) Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14: 7430-7437.